Kenvue at AAD 2026: New Data on Vitamin C, Hydration, Barrier Repair, Acne Care and Next-Generation Sunscreens

Table of Contents

  1. Key Highlights
  2. Introduction
  3. New vitamin C strategy: “Collagen Bank” and protection against UV-induced damage
  4. Hydration and barrier support: Hydro Boost, oat-based therapies and hyaluronic acid preservation
  5. Acne management: balancing efficacy and barrier safety with lower-strength benzoyl peroxide
  6. Sun protection: BEMT, boundary-region light and the daily sunscreen gap
  7. Supporting dermatology practice: Resident training and clinician-facing resources
  8. Hair health and trichology: what Rogaine’s presence signals
  9. Integrating Kenvue’s findings into clinical practice: practical algorithms
  10. Broader industry and regulatory context: filters, formulations and consumer adoption
  11. Limitations and avenues for future research
  12. Practical guidance for clinicians: counseling, prescription, and product selection
  13. Looking ahead: what clinicians and patients should watch for
  14. FAQ

Key Highlights

  • Kenvue’s Neutrogena, Aveeno and Rogaine presented 20 research abstracts at AAD 2026 highlighting advances in vitamin C formulations, oat-based barrier support, hydration for sensitive and post-procedural skin, and acne regimens with improved tolerability.
  • Emerging sunscreen science focused on bis-ethylhexyloxyphenol methoxyphenyl triazine (BEMT) and protection gaps from boundary-region wavelengths (380–430 nm), while consumer research shows persistent underuse of daily sun protection.
  • Clinical education initiatives, including a Resident’s Corner and partnerships with Boards University®, aim to equip dermatology trainees with practical, over-the-counter formulation science and patient-care tools.

Introduction

At the American Academy of Dermatology Annual Meeting in Denver, Kenvue used a combination of clinical abstracts, panels and on-site programming to marshal evidence for everyday dermatologic care. The presentations mapped research from molecular studies to consumer surveys, with practical endpoints clinicians can apply in clinic: preserving barrier function while treating acne, optimizing hydration before and after aesthetic procedures, and advancing sunscreen filters that could broaden spectral protection.

These sessions reflect a broader shift: brand-led research is increasingly aimed at producing products that integrate into medical treatment plans rather than competing with prescription therapies. That strategy is tied to two realities clinicians contend with daily. First, patients want effective, tolerable options they can use long-term for prevention and maintenance. Second, dermatologists need reliable adjuncts that do not undermine medical therapies or recovery from procedures. Kenvue framed its findings around those demands, with new data on vitamin C serums, oat-based barrier support, a tolerable benzoyl peroxide formulation, Hydro Boost for periprocedural skin care, and sunscreen science that directly addresses gaps in current photoprotection.

The following analysis synthesizes the data presented at AAD 2026, explains the mechanisms behind the ingredients and technologies, and outlines practical clinical implications for dermatologists, aestheticians and informed consumers.

New vitamin C strategy: “Collagen Bank” and protection against UV-induced damage

Vitamin C remains a cornerstone of topical photoprotection and skin-repair strategies. Kenvue’s Neutrogena research presented at AAD 2026 tested a 15% vitamin C serum—marketed as Neutrogena Collagen Bank—in cellular and tissue models and reported preservation of skin barrier strength after UV challenge.

How a topical antioxidant supports skin structure Ascorbic acid (vitamin C) acts both as a direct antioxidant and as an essential cofactor in collagen synthesis. It stabilizes collagen triple helices by supporting prolyl and lysyl hydroxylases that crosslink collagen fibrils. Topical vitamin C also scavenges reactive oxygen species generated by ultraviolet (UV) radiation and visible light, reducing downstream signaling that accelerates matrix degradation and inflammation.

The Collagen Bank approach pairs a relatively high vitamin C concentration with formulation strategies meant to maintain barrier integrity. High-dose vitamin C can be irritating for some patients when formulations aren’t optimized. The company’s presentation emphasized dual-action benefits in models exposed to UV radiation: antioxidant protection and preservation of barrier metrics. Preservation of barrier strength is clinically meaningful, particularly for patients using retinoids, undergoing procedures, or with baseline sensitivity.

Translating molecular findings to patient care Laboratory models show mechanisms; real-world outcomes depend on tolerability and adherence. A 15% vitamin C serum that maintains barrier function addresses a major barrier to use: irritation. For patients seeking brightening, protection and anti-aging benefits, such formulations offer an option that may be better tolerated than high-concentration vitamin C serums in simple acidic vehicles. Dermatologists should look for data on formulation pH, stabilizers, delivery systems and the serum’s effect on transepidermal water loss (TEWL) in human volunteers before widespread recommendation. In practice, pairing antioxidant serums with moisturizers that restore lipids and hyaluronic acid can further reduce irritation risk and improve adherence.

Clinical example A 45-year-old patient with photodamage and a history of tretinoin-induced dryness wants to add vitamin C. Choosing a stabilized, barrier-preserving 15% serum could improve collagen support without provoking retinoid intolerance. Start alternate-day application and layer with a ceramide-containing moisturizer. Reassess erythema and TEWL after two weeks to confirm tolerability.

Hydration and barrier support: Hydro Boost, oat-based therapies and hyaluronic acid preservation

Moisturization dominated Kenvue’s clinical program at AAD. Presentations focused on two intersecting needs: durable hydration for clinically sensitive skin and products that preserve or restore barrier function during acne therapy and aesthetic procedures.

Hydro Boost: periprocedural hydration and skin recovery Neutrogena’s Hydro Boost line is formulated around hyaluronic acid (HA) and humectants such as glycerin. A panel—Moisture in Motion—presented data showing Hydro Boost reduced redness and improved smoothness and radiance in patients undergoing non-ablative dermatologic treatments (fraxel, microneedling, chemical peels). Those outcomes are consistent with HA’s ability to increase skin hydration rapidly, plumping the stratum corneum and reducing the visual impact of transient inflammation.

Why hydration matters around procedures Procedures that disrupt stratum corneum integrity increase TEWL, provoke transient inflammation and can accelerate retinoid-related irritation if not managed. An appropriate humectant-rich regimen before and after treatment can minimize downtime and enhance aesthetic outcomes. Hydro Boost-type products offer a low-risk adjunct when chosen for non-comedogenicity and compatibility with the periprocedural plan.

Oat-based barrier repair: filaggrin, loricrin and hyaluronic acid upregulation Aveeno presented data on formulations containing oat ingredients—oat flour and oat beta glucan—that were tested in human skin explants under UV stress. The combination reportedly upregulated hyaluronic acid production in fibroblasts and protected against UV-induced degradation of HA in explants. Additional findings included upregulation of filaggrin and loricrin, two structural proteins critical to barrier resilience.

Mechanistic context Filaggrin breakdown products contribute to natural moisturizing factors in the stratum corneum, promoting hydration and maintaining acid mantle. Loricrin is a major component of the cornified envelope; its expression correlates with barrier competence. Upregulating these proteins supports structural integrity and may reduce sensitivity and TEWL. Oat-derived beta glucans have been studied for their anti-inflammatory and wound-healing properties, and glycerin is a proven humectant.

Comparative moisturization: Aveeno Skin Relief Healing Ointment vs. petrolatum An Aveeno Skin Relief Healing Ointment containing triple oat and glycerin demonstrated superior moisturization and improved surface roughness compared with a leading petrolatum ointment. Petrolatum is an occlusive standard that prevents water loss, but it lacks bioactive ingredients that can actively modify skin biology. The Aveeno study suggests that combining occlusion with bioactive oat ingredients and glycerin yields measurable improvements in hydration and surface texture.

Clinical implications and patient selection

  • For patients with chronic xerosis or atopic-prone skin, oat-based formulations provide barrier support and anti-inflammatory benefits without the heaviness of pure petrolatum.
  • Post-procedural care benefits from humectant-centric products that hydrate without clogging. Hydro Boost products and similar HA/glycerin combinations can be appropriate for many skin types.
  • For occlusion needs (e.g., severe crusting or fissuring), petrolatum remains effective; however, combining occlusive therapy with bioactive creams may accelerate functional recovery.

Patient example A 30-year-old undergoing serial microneedling sessions reports prolonged redness and scaling with a purely occlusive ointment. Switching to a glycerin–HA-rich regimen with oat beta glucan reduces redness and improves comfort while preserving wound healing.

Acne management: balancing efficacy and barrier safety with lower-strength benzoyl peroxide

Acne continues to top the list of concerns for adults under 40. Kenvue presented data on a Neutrogena Clear Pore Cleanser/Mask containing 3.5% benzoyl peroxide (BPO) that produced clinical benefit in acne control while preserving skin feel and improving tolerance.

Benzoyl peroxide: efficacy versus irritation Benzoyl peroxide is bactericidal against Cutibacterium acnes, has mild keratolytic effects and does not induce bacterial resistance. Traditional OTC BPO concentrations include 2.5%, 5% and 10%. Higher concentrations may increase irritation without proportionally greater efficacy. A properly formulated 3.5% product may strike a balance: sufficient antimicrobial activity with lower irritation risk.

Study findings and clinical significance The reported study found that a 3.5% BPO cleanser/mask improved acne appearance and left skin feeling soft and smooth. The dual-use format—cleanser and leave-on mask—offers flexibility and may enhance adherence. For patients who experience dryness or irritation with standard 5% formulations, this lower-strength option can be a valuable alternative. Consider recommending it for daily management, with escalation to higher-strength or prescription agents if clinical response is insufficient.

Practical approach to integrating barrier-safe acne regimens

  • Start BPO in concentrations and formats the patient can tolerate; cleansers and masks that are rinsed off reduce contact time and irritation.
  • Combine BPO with barrier-supportive moisturizers: humectants, ceramides and oat-based ingredients protect the stratum corneum while preserving the antimicrobial effect.
  • During retinoid initiation, stagger topical BPO use (alternate nights or use BPO in the morning) to minimize barrier compromise.
  • Counsel on sun protection; many acne therapies sensitize the skin to UV.

Clinical vignette A 22-year-old with inflammatory papulopustular acne reports irritation with a 5% BPO wash. Switching to a 3.5% BPO cleanser used as a 1–2 minute wash combined with a daily non-comedogenic oat-containing moisturizer improves tolerance and maintains lesion control for three months, avoiding progression to systemic therapy.

Sun protection: BEMT, boundary-region light and the daily sunscreen gap

Suncare was a focal point of Kenvue’s program. Presentations covered technical advances in UV filters—most notably bis-ethylhexyloxyphenol methoxyphenyl triazine (BEMT, also called bemotrizinol)—and studies that revealed gaps in spectral coverage by many sunscreens, particularly at the long UVA/near-visible boundary (380–430 nm). Consumer behavior research showed low prioritization of daily sun protection despite broad awareness of benefits.

BEMT: a broad-spectrum option under consideration BEMT is an organic UV filter widely used in sunscreens outside the United States. It absorbs across a broad UVA and UVB range and adds photostability. Kenvue’s research suggests that formulations using BEMT can be engineered to achieve high SPF and robust UVA protection. Presenters emphasized that formulation matters: BEMT’s performance varies with vehicle and co-ingredients, and careful formulation can harness its full protective capacity.

Why new filters matter Many sunscreens available in the United States lack certain filters approved elsewhere, limiting formulators’ options to achieve both high SPF and high UVA protection without undesirable cosmetic residue. The addition of filters like BEMT could broaden spectral coverage, improve photostability and allow lighter-feeling sunscreens that patients are more likely to use daily.

Boundary-region wavelengths and clinical damage Kenvue-funded studies using Neutrogena Helioplex 360™ examined biological effects of boundary-region light (380–430 nm). Research teams reported pigmentation changes and oxidative biomarker modulation across Fitzpatrick skin types I–VI, as well as clinical demonstration of pigmentation in Fitzpatrick type V after irradiation with deep UVA and high-energy blue light. Those wavelengths fall in the overlap between UVA and visible blue light, and many current filters provide limited coverage in this range.

Clinical consequences

  • Pigmentation and oxidative stress induced by long UVA and high-energy visible light contribute to photoaging and post-inflammatory hyperpigmentation—particularly in darker skin types.
  • Broad-spectrum sunscreens that extend protection into the long UVA and visible range can reduce these outcomes. Formulation innovations and new filters like BEMT may be part of the solution.
  • Consumers and clinicians should recognize that SPF alone does not capture protection across the full damaging spectrum.

Behavioral gap: awareness vs. action Kenvue’s New View of Care Report showed a disconnect: most consumers recognize sun care’s preventative benefits, but only 17% rank it among their top three essential personal care steps. A national survey of 5,000 respondents revealed demographic differences in sun-safe behavior and persistent underuse of UV protection.

Addressing the adherence problem Technical advances alone will not protect patients if products are not used. Clinical strategies to increase sunscreen use include:

  • Recommending cosmetically elegant, lighter-texture formulations for daily use.
  • Counseling on the importance of daily reapplication or incorporation of photoprotective makeup with SPF.
  • Tailoring messaging to patient priorities: framing sunscreen as an anti-aging investment for some, as a hyperpigmentation prevention strategy for others.
  • Encouraging broad-spectrum and high UVA protection, especially for patients with darker phototypes prone to pigmentation.

Real-world example An urban professional with Fitzpatrick IV phototype reports pigmentation flares despite using SPF 30 when outdoors. Education about daily, broad-spectrum protection focused on UVA and visible light, recommending tinted formulations with extended spectral coverage and discussing makeup-integrated SPF improves adherence and reduces recurrences over six months.

Supporting dermatology practice: Resident training and clinician-facing resources

Kenvue emphasized clinician education at AAD 2026. For the first time, a Resident’s Corner provided focused, practical instruction on over-the-counter formulation science. The company partnered with Boards University® and offered scholarship opportunities to attend George Washington University’s Lab to Label conference.

Why clinician education matters Dermatologists are the most trusted source for personal care advice. Providing trainees with formulation literacy—understanding the difference between occlusives, humectants, bioactives and UV filters—improves prescribing and patient counseling. Clinicians who can translate formulation science into actionable product recommendations are better equipped to integrate OTC products into treatment plans and to critique marketing claims.

What to expect from Resident’s Corner programming

  • Practical demonstrations of periprocedural regimens combining humectants and barrier-repair ingredients.
  • Comparative discussions on sunscreens and emerging filters, with attention to real-world application and patient acceptability.
  • Case-based learning on acne regimens that prioritize barrier safety and adherence.

Implications for clinic workflows Clinics that endorse evidence-based OTC adjuncts can shorten recovery times, reduce complication rates from procedures and increase patient satisfaction. Incorporating concise product summaries into patient handouts or electronic aftercare instructions helps standardize recommendations.

Hair health and trichology: what Rogaine’s presence signals

While the press materials focused mainly on skin science, Rogaine’s inclusion in the AAD slate signals continued attention to hair health within a dermatologic framework. Trichological research presented alongside skincare emphasizes integrated approaches to scalp health: preserving barrier function of the scalp, addressing inflammation, and maintaining viable hair follicles through topical agents and patient education.

Clinical takeaways for hair-loss management

  • Scalp hydration and barrier support matter; aggressive shampoos and irritant exposures can exacerbate telogen effluvium and compromise topical therapy adherence.
  • Patient counseling should normalize long timelines for response to minoxidil and set expectations for maintenance therapy.
  • Combining pharmacologic agents with scalp-friendly adjuncts can reduce irritation and support adherence.

Integrating Kenvue’s findings into clinical practice: practical algorithms

The research presented at AAD 2026 points to a pragmatic, product-agnostic algorithm clinicians can adapt. The following framework synthesizes the data and aligns with everyday practice.

  1. Assessment and stratification
  • Evaluate baseline barrier function (subjective dryness, erythema, fissuring) and phototype.
  • Review current topical regimens (retinoids, BPO, exfoliants) and planned procedures.
  1. Pre-procedural optimization
  • For non-ablative procedures, introduce a humectant-rich regimen (HA + glycerin) 1–2 weeks prior to reduce TEWL and prime skin.
  • Avoid starting new potentially irritating actives (high-dose vitamin C, high-concentration BPO) within 1 week of procedure.
  1. Immediate post-procedural care
  • Use non-comedogenic humectant creams and oat-containing formulations to soothe and restore barrier proteins.
  • Reserve occlusives for areas with significant barrier compromise, combining occlusion with active barrier-repair creams on adjacent skin.
  1. Acne management with barrier preservation
  • Initiate BPO at tolerable concentrations: consider 3.5% formulations where available for patients sensitive to 5% solutions.
  • Pair acne therapy with ceramide- and humectant-containing moisturizers to prevent TEWL and irritation.
  • Stagger topical retinoids and BPO if irritation occurs.
  1. Photoprotection strategy
  • Recommend daily, broad-spectrum sunscreen with good UVA coverage and cosmetic acceptability.
  • For patients prone to pigmentary changes, include tinted formulations and discuss additional antioxidants (stabilized vitamin C) to mitigate oxidative damage from long UVA and visible light.
  • Educate patients on reapplication and behavior changes to reduce peak exposure.
  1. Ongoing maintenance and education
  • Monitor tolerability and efficacy at 4–12 week intervals.
  • Use education materials to explain the role of barrier proteins and humectants to patients, reinforcing adherence.

Case application A 28-year-old woman with mild inflammatory acne and Fitzpatrick III skin planning a chemical peel:

  • Pre-peel: Hydro Boost-style HA serum twice daily for one week.
  • During retinoid therapy: reduce frequency 3 days before and after peel.
  • Post-peel: apply oat-containing barrier cream and a soothing HA product; use a 3.5% BPO cleanser when indicated, monitoring for irritation.
  • Sunscreen: recommend tinted, broad-spectrum SPF 50 with daily reapplication.

Broader industry and regulatory context: filters, formulations and consumer adoption

The discussion of BEMT at AAD 2026 connects to wider regulatory and industry dynamics. Many modern filters used globally are not yet available in the U.S., and formulators face trade-offs between SPF, UVA-PF (Persistent Pigment Darkening/critical wavelength considerations), photostability and cosmetic feel. Filters like BEMT, once available, would allow formulators to achieve higher UVA protection without heavy residues, potentially increasing daily use.

Regulatory pathways and product adoption

  • Manufacturers must navigate regulatory approvals and safety dossiers before introducing new filters to markets with stringent requirements.
  • Until such filters are commonly available, formulators will continue to optimize combinations of existing approved filters and cosmetic vehicles to broaden coverage.
  • Clinicians and industry stakeholders can help by participating in clinical conversations that articulate patient needs—emphasizing UVA and visible light protection alongside SPF.

Consumer education and behavioral change Evidence presented at AAD highlights a persistent gap between awareness and action. Changing behavior requires reducing barriers to use (texture, residue, irritation) and framing sunscreen as part of routine care, not an optional extra. Clinicians are central to that narrative: brief, personalized counseling increases uptake and adherence.

Limitations and avenues for future research

The Kenvue data presented span in vitro, ex vivo and clinical contexts, each with limitations. Cell and explant models provide mechanistic insight but cannot fully replicate complex in vivo dynamics. Short-term clinical endpoints—redness after procedures, hydration metrics and early acne outcomes—are valuable but need longer follow-up to assess durability and adherence in diverse populations.

Key questions that remain:

  • Long-term comparative effectiveness of new vitamin C formulations in real-world, diverse patient populations.
  • Durability of barrier protein upregulation (filaggrin, loricrin) with oat-containing formulations beyond acute recovery.
  • Real-world adherence and clinical outcomes when BEMT-containing sunscreens become available in broader markets.
  • Optimization of acne regimens that combine lower-concentration BPO with topical retinoids and modern barrier-repair strategies.

Encouragingly, the AAD presentations suggest a research trajectory that moves from molecular discovery to clinically actionable products and educational programs. Continued independent replication and head-to-head comparisons will clarify product roles and best-use scenarios.

Practical guidance for clinicians: counseling, prescription, and product selection

Clinicians can translate these findings into daily practice with focused, patient-centered advice.

Counseling points to cover in a visit:

  • Explain the role of antioxidants (like vitamin C) for collagen support and photoprotection, emphasizing tolerability and application order (vitamin C in the morning under sunscreen for added UV defense; or evening if tolerance is an issue).
  • Discuss hydration strategies: recommend humectant-rich formulations for pre- and post-procedural care and oat-containing products for patients with sensitivity or barrier compromise.
  • For acne, consider lower-concentration benzoyl peroxide options if irritation limits use; pair with moisturizers that contain glycerin, ceramides or oat derivatives.
  • Reinforce daily sunscreen use tailored to patient preferences—tinted for pigmentation-prone patients, lightweight fluids for oily skin, occlusive ointments for dry skin. Explain UVA and visible light consequences beyond sunburn.

Prescription considerations

  • Reserve systemic therapy for moderate-to-severe acne, but optimize topical regimens first with tolerable BPO options and barrier repair to improve adherence.
  • When introducing combination therapy (retinoids + BPO), set expectations for potential irritation, suggest strategies to minimize it, and schedule early follow-up.

Documentation and patient education

  • Provide concise take-home regimens that list product names, order of application and frequency.
  • Use before-and-after photos where appropriate, but prioritize functional outcomes (reduced redness, less flaking, improved comfort) rather than cosmetic-only endpoints.

Looking ahead: what clinicians and patients should watch for

Several trends deserve close attention as the market and research landscape evolve:

  • New sunscreen filters: Approval and commercialization of filters like BEMT could change sunscreen formulation possibilities in the U.S., offering improved UVA and long-wave coverage with lighter textures.
  • Combination barrier-active products: Formulations that combine humectants, oat-derived bioactives, and mild occlusives may replace blanket recommendations for petrolatum in many scenarios.
  • Tolerable topical acne regimens: Lower-concentration BPO formats and improved vehicles may cut the rate of discontinuation and reduce progression to systemic agents.
  • Training innovations: Greater emphasis on resident education and accessible formulation science will narrow the gap between dermatologic expertise and consumer product use.

Clinicians should monitor peer-reviewed publications building on the AAD abstracts, seek independent replication, and be prepared to adapt regimens as more long-term data become available.

FAQ

Q: What is BEMT and why does it matter? A: BEMT (bis-ethylhexyloxyphenol methoxyphenyl triazine), also called bemotrizinol, is a broad-spectrum UV filter used in sunscreens in many regions outside the United States. It offers wide spectral coverage and photostability. Its inclusion in formulations can improve UVA and long-wave protection and help formulators achieve high SPF with lighter textures, which can increase patient adherence to daily sunscreen use.

Q: How does a 15% vitamin C serum protect against UV-induced damage while preserving the barrier? A: Vitamin C acts as an antioxidant and supports collagen synthesis. In Kenvue’s tissue and cellular models, a 15% vitamin C serum preserved barrier strength after UV exposure, likely by neutralizing reactive oxygen species and supporting matrix integrity. Formulation matters: delivery systems and stabilizers that reduce acidity and irritation help preserve the stratum corneum while delivering antioxidant benefits.

Q: Are oat-based products safe for sensitive or atopic-prone skin? A: Oat-derived ingredients, including oat flour and oat beta glucan, have anti-inflammatory and barrier-supporting properties. Kenvue’s data suggest they upregulate filaggrin and loricrin and augment hyaluronic acid production in response to UV stress. Most patients with sensitive skin tolerate oat-based products well, but clinicians should screen for specific grain sensitivities or contact dermatitis in relevant histories.

Q: Is a 3.5% benzoyl peroxide formulation effective for acne? A: The Neutrogena study presented at AAD 2026 reported that a 3.5% benzoyl peroxide cleanser/mask improved acne appearance and provided good tolerability. Lower concentrations can reduce irritation while maintaining antimicrobial effects. Clinicians should individualize therapy: if lesion counts and severity warrant stronger therapy, escalate accordingly; if irritation limits adherence, consider lower concentrations and barrier-supportive moisturizers.

Q: What are boundary-region wavelengths and how should patients protect against them? A: Boundary-region wavelengths sit between long UVA and high-energy visible blue light (approximately 380–430 nm). Studies show these wavelengths can induce pigmentation and oxidative stress, particularly in darker skin types. Protection strategies include broad-spectrum sunscreens with good UVA/visible light coverage (tinted sunscreens help), antioxidants like stabilized vitamin C, and behavioral measures (shade, hats, reducing peak exposures).

Q: How can dermatology residents and trainees benefit from the Resident’s Corner and similar programs? A: Resident-focused programming provides practical formulation literacy—understanding ingredient classes, mechanisms and product selection. That knowledge improves clinical recommendations and patient education. Residents gain exposure to periprocedural regimens, sun-protection nuances and evidence-based OTC adjuncts, which supports evidence-based practice and strengthens the bridge between clinical care and consumer product science.

Q: How soon should clinicians expect to see products using new filters like BEMT in the United States? A: Product availability depends on regulatory approvals and manufacturer timelines. Manufacturers must submit safety and efficacy dossiers and await regulatory review. Clinicians should watch peer-reviewed studies, regulatory announcements and professional discussions for updates on new filter approvals and commercial launches.

Q: What are immediate steps clinicians can take to apply Kenvue’s findings? A: Start by evaluating barrier function in all patients before initiating potentially irritating therapies. Incorporate humectants (hyaluronic acid, glycerin) and oat-derived barrier repair products into pre- and post-procedural protocols. Consider lower concentration BPO options for acne patients with intolerance to higher percentages. Emphasize daily, broad-spectrum sunscreen with good UVA/visible light coverage and counsel on adherence and reapplication.

Q: Will these product innovations replace prescription therapies? A: No. The products and formulations discussed are positioned as complementary tools—adjuncts to prescription therapies and procedural care. They can reduce irritation, improve recovery and support long-term maintenance, but moderate-to-severe conditions will still require appropriate medical therapy.

Q: Where can clinicians find more detailed data from the AAD presentations? A: Abstracts and presentations from the American Academy of Dermatology Annual Meeting are typically available through the meeting’s program, associated journals and publisher websites. Clinicians should consult the full abstracts and peer-reviewed follow-ups for methodological details and statistical analysis before changing practice patterns.

This reporting synthesizes evidence presented by Kenvue’s brands at AAD 2026 and translates mechanisms into clinical guidance. It highlights practical pathways for integrating barrier-preserving antioxidants, humectant-based hydration strategies, oat-derived barrier repair, tolerable acne formulations and expanded sun protection into everyday dermatologic care. Continued independent replication and longer-term clinical outcomes will determine how broadly these products reshape routine practice, but the research presented provides a foundation clinicians can use now to improve tolerance, adherence and outcomes for many patients.